Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2Smoking Cessation 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Echocardiography 14Doxorubicin 10Exercise 8Electrocardiography 7Trastuzumab 6Cyclophosphamide 5Carvedilol 5Docetaxel 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Social Determinants of Health 2Silymarin 2Magnetic Resonance Spectroscopy 2Ivabradine 2High-Intensity Interval Training 2Exercise Test 2Chemoradiotherapy 2Blood Specimen Collection 2Bisoprolol 2Antineoplastic Agents 2Anthracyclines 2sulforaphane 1schizandrin 1pegfilgrastim 1nicotinamide-beta-riboside 1mitoquinone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cardiotoxicity × sulforaphane × Clear all
NCT03934905 2024-11-20

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Texas Tech University Health Sciences Center

Phase 1/2 Recruiting
70 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡